Ascentage Pharma Advances Global Phase III Trial for Lisaftoclax in Higher-Risk MDS Treatment
Ascentage Pharma's GLORA-4 Phase III trial of lisaftoclax, a potential breakthrough for higher-risk myelodysplastic syndrome (MDS), receives FDA and EMA clearance, marking a significant step towards addressing a critical unmet medical need in oncology.
Ascentage Pharma has initiated enrollment for its GLORA-4 Phase III trial, a global study evaluating the efficacy and safety of lisaftoclax in combination with azacitidine for treating newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS). This trial, cleared by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), represents a pivotal moment in the quest for innovative treatments for HR-MDS, a condition with limited therapeutic options and poor prognosis.
The GLORA-4 study is notable for being the only registrational Phase III trial globally for a Bcl-2 inhibitor in HR-MDS. Lisaftoclax, Ascentage Pharma's proprietary Bcl-2 inhibitor, has shown promising clinical benefits and tolerability in earlier studies. The trial's success could potentially fill a longstanding gap in HR-MDS treatment, offering hope to patients worldwide.
Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, emphasized the significance of this development, stating, "The clearances of the GLORA-4 study by the U.S. FDA and EMA pave the way for lisaftoclax to potentially become the first Bcl-2 inhibitor approved globally for first-line treatment of higher-risk MDS." This trial is being conducted simultaneously in China, the U.S., and Europe, aiming to accelerate the drug's path to market authorization.
HR-MDS is a severe myeloid clonal disease with a high risk of progression to acute myeloid leukemia (AML). Current treatments, including hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (allo-HSCT), offer limited efficacy and are associated with significant challenges. The GLORA-4 trial seeks to evaluate whether lisaftoclax in combination with AZA can improve outcomes for these patients, based on preliminary data showing an overall response rate of 75%, significantly higher than HMAs alone.
The global co-leading principal investigators, Dr. Guillermo Garcia-Manero and Prof. Xiaojun Huang, highlighted the urgent need for innovative therapies in HR-MDS. Prof. Huang noted, "The compelling response rate and manageable safety profile observed in earlier studies of lisaftoclax are very encouraging." Dr. Garcia-Manero added, "We hope these characteristics of lisaftoclax will make it a potentially superior treatment option for patients."
For more information on Ascentage Pharma and its research, visit https://ascentage.com/.